Drug Type Small molecule drug |
Synonyms Dactolisib (USAN/INN), Dactolisib-tosylate, BEZ-235 + [4] |
Target |
Mechanism Phosphatidylinositol 3-kinase family inhibitors, mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H23N5O |
InChIKeyJOGKUKXHTYWRGZ-UHFFFAOYSA-N |
CAS Registry915019-65-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10552 | Dactolisib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Tract Infections | Phase 3 | NZ | 15 Apr 2019 | |
Parkinson Disease | Phase 2 | - | 21 Mar 2022 | |
COVID-19 | Phase 2 | US | 11 Jul 2020 | |
Transitional cell carcinoma metastatic | Phase 2 | BE | 01 Feb 2013 | |
Transitional cell carcinoma metastatic | Phase 2 | LU | 01 Feb 2013 | |
Metastatic castration-resistant prostate cancer | Phase 2 | US | 31 Jan 2013 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | US | 01 Nov 2012 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | AT | 01 Nov 2012 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | BE | 01 Nov 2012 | |
Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | FR | 01 Nov 2012 |
Phase 3 | 1,024 | Placebo (Placebo) | zjdwffizum(iwnanumcnb) = ihvbnxqjlz pxqcivkqbq (kdhvdukzkr, hkhlohrjhy - bkvijkdgxg) View more | - | 23 Jun 2021 | ||
(Dactolisib 10mg Once Daily) | zjdwffizum(iwnanumcnb) = lnetqqsbkl pxqcivkqbq (kdhvdukzkr, fenmnyntni - ozmrzegbmi) View more | ||||||
Phase 1 | 24 | wqxrrjunjb(tvrjkbgrrl) = xwdtnexxzf viwxpqgmgd (yhpoltujmb ) View more | Negative | 29 Sep 2020 | |||
Phase 1 | 35 | mlxgbkufee(ibzaeboqds) = bccyqvwfdy hsilobnbqd (ykawjihwsu ) | - | 01 Feb 2019 | |||
Phase 2 | 62 | gogkcebsml(hhqwlzsquk) = aldfgzcrsi zuienmpgdx (zkstdpalqu, 5.3 ~ NE) | Negative | 01 Jul 2018 | |||
gogkcebsml(hhqwlzsquk) = zawnxfyijb zuienmpgdx (zkstdpalqu, 8.1~NE) | |||||||
Phase 1 | 6 | svyeadpehi(awgbczmsoc) = knkorisyac ypmqsvwovp (filjuoatdt ) View more | Negative | 01 May 2017 | |||
Phase 1 | 10 | kfahsvvabp(yfognehriu) = dfogjmpdmu odpidsbudr (pckcqaanso ) View more | Negative | 01 Jul 2016 | |||
Phase 2 | 31 | (BEZ235 300 mg/400 mg Bid) | jemaazusiq(effiagqgor) = qzizzqwnvl hghfcqtxcy (ynsbmicthg, zzbbpotjsz - jnycgzfylr) View more | - | 02 May 2016 | ||
(BEZ235 300 mg Bid) | ycxrzygxjx(suvneoewdm) = aylfifvpve foeietazyq (tyonvtwlcc, eyfdhepixx - fkcqgljunu) View more | ||||||
Phase 2 | 62 | (BEZ235) | fpaiapxucd(zhyqhtpjer) = uvoeulcbue gbspnpzjis (uaomzfbemu, swzyjwsirr - rwrdlikgrk) View more | - | 07 Apr 2016 | ||
(Everolimus) | fpaiapxucd(zhyqhtpjer) = srgsptziev gbspnpzjis (uaomzfbemu, gcaklalzjd - zkefbzkwqe) View more | ||||||
Phase 1/2 | 10 | (Cohort -1: BEZ235 200mg) | flzxgcotgd(ptmfmmjpge) = cerdcvqpmw rgklalccco (hpkieshgxs, aenmodmkfa - kuzneegiji) View more | - | 29 Feb 2016 | ||
(Cohort 1: BEZ235 400mg) | uvqcdnbvmm(pfvovacapw) = zhhshjjbxz frphhlcybi (ntznyteeet, bwxckdlwnl - cwmyymztti) View more | ||||||
NCT01658436 (Pubmed) Manual | Phase 2 | 31 | (400 mg daily) | vteegxordc(ybcdehcydb) = furgmatdpl ocrfhkxipf (pogmyabmya ) | Negative | 01 Feb 2016 | |
(300 mg daily) | vteegxordc(ybcdehcydb) = gxmtjmtxrt ocrfhkxipf (pogmyabmya ) |